N-Nitrosopyrrolidine

CASRN 930-55-2

  • IRIS Summary (PDF) (10 pp, 102 K)
  • Status: N-Nitrosopyrrolidine is not being reassessed by IRIS at this time.

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (10 pp, 102 K)
Not assessed under the IRIS Program.

Reference Concentration for Inhalation Exposure (RfC) (PDF) (10 pp, 102 K)
Not assessed under the IRIS Program.

Cancer Assessment


Weight of Evidence for Cancer (PDF) (10 pp, 102 K) last updated: 01/31/1987

WOE Characterization Framework for WOE Characterization
B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Basis:
  • Tumors at more than one site have been observed in two rodent species administered nitrosopyrrolidine orally.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (10 pp, 102 K)

Oral Slope Factor: 2.1 per mg/kg-day
Drinking Water Unit Risk: 6.1 x10 -5 per µg/L
Extrapolation Method: Linearized multistage procedure, extra risk
Tumor site(s): Hepatic
Tumor type(s): Hepatocellular carcinoma and adenoma (Preussmann et al., 1977)


Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (10 pp, 102 K)

Inhalation Unit Risk: 6.1 x10 -4 per µg/m3
Extrapolation Method: Linearized multistage procedure, extra risk
Tumor site(s): Hepatic
Tumor type(s): Hepatocellular carcinoma and adenoma (Preussmann et al., 1977)


You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.